BIOMAT Database Logo BIOMAT Database Logo

Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma. 1994

C H Veenhof, and M E van der Burg, and M Nooy, and J G Aalders, and S Pecorelli, and C F Oliveira, and N Rotmensz, and J B Vermorken
Division of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands.

The EORTC Gynaecological Cancer Cooperative Group conducted a phase II study of high dose oral megestrol acetate: 800 mg/day for 1 month followed by 400 mg/day as maintenance treatment, in heavily pretreated patients with ovarian cancer. Of 72 patients included in this study, 54 were fully evaluable for response and toxicity. The response rate was low with only 1 patient having a partial response, 9 patients with stable disease and 44 patients with progressive disease. The toxicity profile was low. However, 1 patient died after 2 months of treatment, and in 3 patients thrombo-embolic events occurred. Weight gain varied in 20 of the 61 patients from 0.5 to 16 kg. This study does not suggest that the overall 10% benefit from hormonal therapy for chemotherapy refractory ovarian cancer will improve by increasing the dose.

UI MeSH Term Description Entries
D008535 Megestrol A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer. 17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione,Pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl-
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009376 Neoplasms, Hormone-Dependent Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment. Hormone-Dependent Neoplasms,Hormone Dependent Neoplasms,Hormone-Dependent Neoplasm,Neoplasm, Hormone-Dependent,Neoplasms, Hormone Dependent
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

C H Veenhof, and M E van der Burg, and M Nooy, and J G Aalders, and S Pecorelli, and C F Oliveira, and N Rotmensz, and J B Vermorken
Phase II study of high-dose megestrol acetate in patients with advanced malignant melanoma.
May 1982, Cancer treatment reports,
C H Veenhof, and M E van der Burg, and M Nooy, and J G Aalders, and S Pecorelli, and C F Oliveira, and N Rotmensz, and J B Vermorken
Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer.
October 2001, Anti-cancer drugs,
C H Veenhof, and M E van der Burg, and M Nooy, and J G Aalders, and S Pecorelli, and C F Oliveira, and N Rotmensz, and J B Vermorken
High-dose megestrol acetate therapy of ovarian carcinoma: a phase II study by the Northern California Oncology Group.
December 1986, Seminars in oncology,
C H Veenhof, and M E van der Burg, and M Nooy, and J G Aalders, and S Pecorelli, and C F Oliveira, and N Rotmensz, and J B Vermorken
High-dose medroxyprogesterone acetate (MPA) in advanced chemotherapy-resistant ovarian carcinoma: a phase II study.
February 1982, Cancer treatment reports,
C H Veenhof, and M E van der Burg, and M Nooy, and J G Aalders, and S Pecorelli, and C F Oliveira, and N Rotmensz, and J B Vermorken
Megestrol acetate for the palliation of advanced ovarian carcinoma.
January 1983, Obstetrics and gynecology,
C H Veenhof, and M E van der Burg, and M Nooy, and J G Aalders, and S Pecorelli, and C F Oliveira, and N Rotmensz, and J B Vermorken
High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
February 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
C H Veenhof, and M E van der Burg, and M Nooy, and J G Aalders, and S Pecorelli, and C F Oliveira, and N Rotmensz, and J B Vermorken
Hemostatic effects of high-dose megestrol acetate therapy in patients with advanced gynecological cancer.
October 2001, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology,
C H Veenhof, and M E van der Burg, and M Nooy, and J G Aalders, and S Pecorelli, and C F Oliveira, and N Rotmensz, and J B Vermorken
Phase II study of megestrol acetate in the treatment of hepatocellular carcinoma.
April 1997, Journal of gastroenterology and hepatology,
C H Veenhof, and M E van der Burg, and M Nooy, and J G Aalders, and S Pecorelli, and C F Oliveira, and N Rotmensz, and J B Vermorken
Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer.
January 1990, Journal of cancer research and clinical oncology,
C H Veenhof, and M E van der Burg, and M Nooy, and J G Aalders, and S Pecorelli, and C F Oliveira, and N Rotmensz, and J B Vermorken
Phase II study of high-dose medroxyprogesterone acetate in advanced malignant melanoma.
June 1989, British journal of cancer,
Copied contents to your clipboard!